Indication · advanced sm in june 2021 and indolent sm in may 2023

advanced sm in june 2021 and indolent sm in may 2023 FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 1 advanced sm in june 2021 and indolent sm in may 2023 drug. 1 FDA approval recorded, most recently AYVAKIT® (avapritinib) on May 2023.

Drugs

DrugSponsorModalityDesignations
AYVAKIT® (avapritinib)SNYsmall_molecule—

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
May 2023Month disclosedAYVAKIT® (avapritinib)SNYFDA approvaladvanced SM in June 2021 and indolent SM in May 2023ApprovedSEC 8-K Exhibit 99.1

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.

Questions

What advanced sm in june 2021 and indolent sm in may 2023 drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.